Acknowledgement
We thank Yafei Chen for the technical support.
References
- Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-1846 https://doi.org/10.1016/S0140-6736(16)00587-0
- Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-1813 https://doi.org/10.1056/NEJMoa1510665
- Queirolo P, Spagnolo F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review. Cancer Treat Rev 2017;59:71-78 https://doi.org/10.1016/j.ctrv.2017.07.002
- Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541-3543 https://doi.org/10.1200/JCO.2015.61.6870
- Raimondi A, Randon G, Sepe P, Claps M, Verzoni E, De Braud F, et al. The evaluation of response to immunotherapy in metastatic renal cell carcinoma: open challenges in the clinical practice. Int J Mol Sci 2019;20:4263
- Wong AS, Thian YL, Kapur J, Leong CN, Kee P, Lee CT, et al. Pushing the limits of immune-related response: a case of "extreme pseudoprogression". Cancer Immunol Immunother 2018;67:1105-1111 https://doi.org/10.1007/s00262-018-2167-3
- Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920-1928 https://doi.org/10.1158/1078-0432.CCR-16-1741
- Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, et al. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol 2018;36:1703-1709 https://doi.org/10.1007/s00345-018-2264-0
- Carter BW, Bhosale PR, Yang WT. Immunotherapy and the role of imaging. Cancer 2018;124:2906-2922 https://doi.org/10.1002/cncr.31349
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247 https://doi.org/10.1016/j.ejca.2008.10.026
- Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Janne PA, et al. Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. J Immunother Cancer 2016;4:84
- Kim HK, Heo MH, Lee HS, Sun JM, Lee SH, Ahn JS, et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol 2017;80:591-598 https://doi.org/10.1007/s00280-017-3396-4
- Khoja L, Kibiro M, Metser U, Gedye C, Hogg D, Butler MO, et al. Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. Br J Cancer 2016;115:1186-1192 https://doi.org/10.1038/bjc.2016.308
- Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 2018;88:38-47 https://doi.org/10.1016/j.ejca.2017.10.017
- Bohnsack O, Hoos A, Ludajic K. Adaptation of the immune related response criteria: irRECIST. Ann Oncol 2014;25:iv369
- Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013;19:3936-3943 https://doi.org/10.1158/1078-0432.CCR-13-0895
- Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-7420 https://doi.org/10.1158/1078-0432.CCR-09-1624
- Wei H, Jiang H, Song B. Role of medical imaging for immune checkpoint blockade therapy: from response assessment to prognosis prediction. Cancer Med 2019;8:5399-5413 https://doi.org/10.1002/cam4.2464
- Thallinger C, Fureder T, Preusser M, Heller G, Mullauer L, Holler C, et al. Review of cancer treatment with immune checkpoint inhibitors: current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr 2018;130:85-91 https://doi.org/10.1007/s00508-017-1285-9
- Nishino M, Hatabu H, Hodi FS. Imaging of cancer immunotherapy: current approaches and future directions. Radiology 2018;290:9-22 https://doi.org/10.1148/radiol.2018181349
- Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-e152 https://doi.org/10.1016/S1470-2045(17)30074-8
- Ferte C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 2014;20:246-252 https://doi.org/10.1158/1078-0432.CCR-13-2098
- Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 2011;47:2512-2516 https://doi.org/10.1016/j.ejca.2011.06.012
- Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018;4:1543-1552 https://doi.org/10.1001/jamaoncol.2018.3676
- Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016;34:1510-1517 https://doi.org/10.1200/JCO.2015.64.0391
- Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 2018;15:748-762 https://doi.org/10.1038/s41571-018-0111-2
- Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015;16:293-300 https://doi.org/10.1016/S1470-2045(14)71222-7
- Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res 2017;23:4671-4679 https://doi.org/10.1158/1078-0432.CCR-17-0114
- Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, et al. Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer. J Thorac Oncol 2018;13:978-986 https://doi.org/10.1016/j.jtho.2018.04.010
- Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Janne PA, et al. Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: imaging markers for treatment outcome. Clin Cancer Res 2017;23:5737-5744 https://doi.org/10.1158/1078-0432.CCR-17-1434
- Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004-2012 https://doi.org/10.1200/JCO.2014.58.3708
- Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur Urol 2017;72:368-376 https://doi.org/10.1016/j.eururo.2017.03.037